Some scholars conducted in vitro studies, as well as subcutaneous tumor transplantation and peritoneal metastasis tumor survival models in mice with esophageal adenocarcinoma, and found that compared to conventional paclitaxel, nanoparticle-bound albumin-paclitaxel showed significantly improved in vivo antitumor efficacy and overall survival rates, whether used alone or in combination therapy (Hassan et al., 2017). Here, ALB is linked to esophageal adenocarcinoma.